The Senate Finance Committee voted 15 to 12 on Thursday to advance Chris Klomp's nomination as deputy secretary of Health and Human Services, sending him to the full Senate for a final vote, STAT reported. Sen. Sheldon Whitehouse of Rhode Island was the only Democrat to join all Republicans in supporting him. A date for the floor vote has not been announced.
If confirmed, Klomp would become the department's second-highest official. The deputy helps run daily operations across agencies including Medicare, Medicaid, the CDC, the FDA, and the National Institutes of Health. That puts the job close to decisions families feel directly, from how quickly vaccines reach pediatricians to how drug pricing deals are carried out.
The vote came as the committee's top Democrat pointed to a month-long disruption in the federal program that supplies free vaccines to nearly half of the nation's children. That program has since resumed, but the episode shaped how senators framed the vote.
A Mostly Party-Line Vote Shaped by Vaccine Concerns
Committee Chairman Mike Crapo of Idaho praised Klomp's focus on operational excellence and measurable results, according to Roll Call. Whitehouse had earlier called Klomp "very proficient" on the technical aspects of health policy.
Sen. Ron Wyden of Oregon, the committee's ranking Democrat, opposed the nomination. He criticized the administration's drug price agreements with pharmaceutical companies as opaque and pointed to the CDC's Vaccines for Children program, where doctors had been unable to get updated COVID vaccines for about a month. Wyden said, "The vaccine chaos that we've come to expect from Robert Kennedy's HHS continues."
During the confirmation hearings, Democrats and Sen. Bill Cassidy of Louisiana, a Republican physician who chairs the Senate health committee, urged Klomp to push back if vaccine policy continued to be undermined, STAT reported. Cassidy pressed him on the CDC's refusal to report certain measles-related deaths in Pennsylvania. "People are dying. The American people should know that," Cassidy said.
The committee also voted 14 to 13 to advance Ge Bai as HHS assistant secretary for planning and evaluation. Both nominations now head to the Senate floor.
A Nominee Who Already Holds Significant Influence
MedicalDaily previously reported that Klomp told the committee that the MMR vaccine is the most effective tool against measles and that he did not believe the vaccine causes autism. Since that hearing, the question has shifted from what Klomp says about vaccines to how he would use formal authority over the department's operations.
Klomp already wields significant power. He serves as a senior adviser and chief counselor to HHS Secretary Robert F. Kennedy Jr., previously oversaw the Medicare program, and helped broker the administration's most-favored-nation drug pricing deals with manufacturers. At his hearing, he said his responsibilities include personnel and the smooth operation of the department.
The deputy post has been vacant since Jim O'Neill, who also served as acting CDC director, left HHS on Feb. 13 as part of a leadership shakeup, CNN reported at the time. Confirmation would give Klomp formal authority over the department's day-to-day management during a period of heavy turnover.
The Household Stakes of the Deputy Job
For most families, the deputy secretary's influence is felt through logistics rather than headlines. The Vaccines for Children program resumed COVID vaccine ordering on Sept. 23 after nearly a month in limbo, according to a KFF Health News summary of Washington Post reporting. Delays like that fall hardest on low-income families and on clinics that rely on the federal supply.
Medicaid enrollees could also feel the effects of Klomp's drug pricing work. Forty states and Puerto Rico had signed on to a Medicaid most-favored-nation pricing model ahead of a Sept. 30 deadline, MedicalDaily reported, although STAT has reported that the administration overstated states' interest. Senate Democrats say the underlying contracts with drugmakers have not been made public, which limits how well families can judge the savings.
Older adults are affected too. Medicare open enrollment begins Oct. 15. Enrollees comparing plans this fall should review drug coverage and costs directly, since federal pricing deals do not automatically lower every plan's copays.
The committee vote does not change any vaccine recommendation or coverage rule. CDC guidance still recommends the two-dose MMR series for children. Parents with questions about vaccines, including COVID shots now available again through the Vaccines for Children program, should talk with their child's clinician before delaying a dose.
What remains unknown is how Klomp would use the post on vaccines, where his public statements have been more supportive than some of the department's recent actions. STAT reported that Klomp is expected to be confirmed.
Key Questions Answered
What happened in the Senate Finance Committee? The committee voted 15 to 12 on Sept. 24 to advance Chris Klomp's nomination as HHS deputy secretary.
Is Klomp confirmed? No. The full Senate must still vote, and no date has been announced.
Who crossed party lines? Sen. Sheldon Whitehouse was the only Democrat to vote for Klomp.
Why did vaccine policy dominate the debate? Senators cited disruptions in the Vaccines for Children program and the CDC's handling of measles deaths while questioning how Klomp would respond.
What does the deputy secretary do? The deputy helps run daily operations across HHS agencies, including Medicare, Medicaid, the CDC, the FDA, and NIH.
Does this change vaccine recommendations? No. Current CDC guidance, including the two-dose MMR series, remains in place.
Published by Medicaldaily.com
